Haemostatic Studies in Uraemic Patients Following DDAVP Administration

[1]  A. Schwartz,et al.  Desmopressin-induced improvement in bleeding times in chronic renal failure patients correlates with platelet serotonin uptake and ATP release. , 1990, The American journal of the medical sciences.

[2]  J. Disa,et al.  Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. , 1990, Thrombosis research.

[3]  W. Hathaway,et al.  Use of DDAVP in inherited and acquired platelet dysfunction , 1990, American journal of hematology.

[4]  M. Grant,et al.  Desmopressin Stimulates Parallel Norepinephrine and Tissue Plasminogen Activator Release in Normal Subjects and Patients with Diabetes Mellitus , 1988, Thrombosis and Haemostasis.

[5]  M. Blombäck,et al.  DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. , 1987, Thrombosis research.

[6]  J. Ingerslev,et al.  The multimeric structure of plasma F VIII:RAg studied by electroelution and immunoperoxidase detection. , 1986, Thrombosis research.

[7]  B. Wiman,et al.  Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. , 1986, Clinical chemistry.

[8]  A. Bloom,et al.  The effect of desamino‐D‐arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities , 1984, British journal of haematology.

[9]  M. Cheang,et al.  SHORTENING OF BLEEDING TIME BY 1-DEAMINO-8-D-ARGININE VASOPRESSIN IN VARIOUS BLEEDING DISORDERS , 1984, The Lancet.

[10]  M. Schalekamp,et al.  The Inability of Propranolol and Aspirin to Inhibit the Response of Fibrinolytic Activity and Factor VIII-Antigen to Infusion of DDAVP , 1984, Thrombosis and Haemostasis.

[11]  P. Mannucci,et al.  Effect of Des-Amino-D-Arginine Vasopressin (DDAVP) on Plasma Levels of Platelet and Endothelial Cell Release Products , 1983, Thrombosis and Haemostasis.

[12]  G. Remuzzi,et al.  Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. , 1983, The New England journal of medicine.

[13]  P. Mannucci,et al.  Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes , 1982 .

[14]  H. J. Olverman,et al.  5‐HYDROXYTRYPTAMINE AND DOPAMINE TRANSPORT BY RAT AND HUMAN BLOOD PLATELETS , 1978, British journal of pharmacology.

[15]  P. Mannucci,et al.  1-DEAMINO-8-D-ARGININE VASOPRESSIN: A NEW PHARMACOLOGICAL APPROACH TO THE MANAGEMENT OF HAEMOPHILIA AND VON WILLEBRAND'S DISEASE , 1977, The Lancet.

[16]  C. Mielke,et al.  The standardized normal Ivy bleeding time and its prolongation by aspirin. , 1969, Blood.

[17]  C. Laurell,et al.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. , 1966, Analytical biochemistry.

[18]  G. Ashcroft,et al.  ESTIMATION OF 5-HYDROXYTRYPTAMINE IN HUMAN BLOOD. , 1964, Clinica chimica acta; international journal of clinical chemistry.

[19]  W. Buczko,et al.  Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients. , 1990, Folia haematologica.

[20]  N. Baumslag.  Letter: Lead poisoning. , 1975, Lancet.